title: A Joint Model for the Kinetics of CTC Count and PSA Concentration During Treatment in Metastatic Castration-Resistant Prostate Cancer.
abstract: Assessment of treatment efficacy in metastatic castration-resistant prostate cancer (mCRPC) is limited by frequent nonmeasurable bone metastases. The count of circulating tumor cells (CTCs) is a promising surrogate marker that may replace the widely used prostate-specific antigen (PSA). The purpose of this study was to quantify the dynamic relationships between the longitudinal kinetics of these markers during treatment in patients with mCRPC. Data from 223 patients with mCRPC treated by chemotherapy and/or hormonotherapy were analyzed for up to 6 months of treatment. A semimechanistic model was built, combining the following several pharmacometric advanced features: (1) Kinetic-Pharmacodynamic (K-PD) compartments for treatments (chemotherapy and hormonotherapy); (2) a latent variable linking both marker kinetics; (3) modeling of CTC kinetics with a cell lifespan model; and (4) a negative binomial distribution for the CTC random sampling. Linked with survival, this model would potentially be useful for predicting treatment efficacy during drug development or for therapeutic adjustment in treated patients.
authors.affiliation: EMR 3738, Ciblage Thérapeutique en Oncologie, Faculté de Médecine et de Maïeutique Lyon-Sud Charles Mérieux, Université Claude Bernard Lyon 1 Oullins, France.
authors.forename: M
authors.initials: M
authors.lastname: Wilbaux
authors.affiliation: EMR 3738, Ciblage Thérapeutique en Oncologie, Faculté de Médecine et de Maïeutique Lyon-Sud Charles Mérieux, Université Claude Bernard Lyon 1 Oullins, France.
authors.forename: M
authors.initials: M
authors.lastname: Tod
authors.affiliation: Royal Marsden Hospital London, UK.
authors.forename: J
authors.initials: J
authors.lastname: De Bono
authors.affiliation: Royal Marsden Hospital London, UK.
authors.forename: D
authors.initials: D
authors.lastname: Lorente
authors.affiliation: Royal Marsden Hospital London, UK.
authors.forename: J
authors.initials: J
authors.lastname: Mateo
authors.affiliation: EMR 3738, Ciblage Thérapeutique en Oncologie, Faculté de Médecine et de Maïeutique Lyon-Sud Charles Mérieux, Université Claude Bernard Lyon 1 Oullins, France ; Service d'Oncologie Médicale, Investigational Center for Treatments in Oncology and Hematology of Lyon, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon Pierre-Bénite, France.
authors.forename: G
authors.initials: G
authors.lastname: Freyer
authors.affiliation: EMR 3738, Ciblage Thérapeutique en Oncologie, Faculté de Médecine et de Maïeutique Lyon-Sud Charles Mérieux, Université Claude Bernard Lyon 1 Oullins, France ; Service d'Oncologie Médicale, Investigational Center for Treatments in Oncology and Hematology of Lyon, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon Pierre-Bénite, France.
authors.forename: B
authors.initials: B
authors.lastname: You
authors.affiliation: EMR 3738, Ciblage Thérapeutique en Oncologie, Faculté de Médecine et de Maïeutique Lyon-Sud Charles Mérieux, Université Claude Bernard Lyon 1 Oullins, France.
authors.forename: E
authors.initials: E
authors.lastname: Hénin